electroCore, Inc. announces the launch of a new online store


ROCKAWAY, NJ, December 15, 2021 (GLOBE NEWSWIRE) – electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of a boutique e-commerce platform for patients residing in the United Kingdom. The site, which can be found at www.gammacore.co.uk, asks patients to complete a health questionnaire in order to purchase a gammaCore Sapphire ™ vagus nerve stimulation (nVNS) device online.

The first product launched on the platform is designed to treat menstrual migraine, supporting the 60% of women who report migraine symptoms associated with their menstrual cycle. This platform will allow patients to have a fully virtual experience by performing an online clinical assessment, having the product delivered to their doorstep and taking training via video calls with a member of the Kingdom’s customer service team. -United.

“We want to make gammaCore more accessible to patients looking to better manage their primary headache. With around 70% of migraine sufferers being female, the specificity of menstrual migraine is a natural starting point in a new chapter for our activity in the online marketplace. We have created a simple assessment process with full clinician supervision providing ongoing customer service as needed, ”said Karly Hoggard, director of global business development at electroCore. “Many women with migraine symptoms every month expect to live with such symptoms, which impact daily life, work, family and social commitments. We’re excited to provide a clinically proven option for women looking for solutions to treat their primary headaches, and through this platform, we hope to empower people to take ownership of their disease and get back on their feet. control. “

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes with its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of several conditions in neurology. The current indications of the company are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and cluster headache episodic, the acute and preventive treatment of migraine in the adolescent and paroxysmal hemicrania and continuous hemicrania in adults.

For more information, visit www.electrocore.com.

About gammaCoreMT
gammaCoreMT (nVNS) is the first non-invasive portable medical treatment applied to the neck as an adjunct to treat migraine and cluster headaches of the face through the use of mild electrical stimulation of the vagus nerve that passes through the skin. Designed as portable and easy to use technology, gammaCore can be self-administered by patients as needed without the potential side effects associated with commonly prescribed medications. When placed on a patient’s neck above the vagus nerve, gammaCore stimulates the afferent fibers of the nerve, which can lead to reduced pain in patients.

gammaCore (nVNS) is cleared by the FDA in the United States for adjuvant use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients and the acute and preventive treatment of migraine in adolescents (12 years and older) and adult patients. gammaCore is CE marked in the European Union for the acute and / or prophylactic treatment of primary headache (migraines, cluster headache, trigeminal autonomic headache and continuous bleeding) and headache from drug abuse in adults.

gammaCore is contraindicated in patients if they:

  • Have an active implantable medical device, such as a pacemaker, hearing aid implant, or other electronic device implanted
  • Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
  • Use another device at the same time (eg TENS unit, muscle stimulator) or any other portable electronic device (eg cell phone)

The safety and efficacy of gammaCore have not been evaluated in the following patients:

  • Adolescent patients with congenital heart problems
  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients (under 12 years old)
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia or tachycardia

Please refer to the gammaCore Instructions for Use for all important warnings and precautions before using or prescribing this product.

For more information, please visit www.gammacore.co.uk.

Forward-looking statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the activities of electroCore. prospects and plans for clinical and product development; its pipeline or potential markets for its technologies; the timing, results and impact of regulatory, clinical and commercial developments; the Company’s UK business prospects (including its e-commerce initiative) and other new markets and other statements which are not historical in nature, particularly those which use terms such as “anticipates” , “Will”, “expects”, “estimates,” “intends”, other words with similar meanings, derivations of these words and the use of future dates. Actual results could differ from those projected in forward-looking statements as a result of many factors. These factors include, among others, the ability to raise additional funds necessary to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with development of new products or technologies, the ability to commercialize gammaCore ™, the impact and potential effects of COVID-19 on electroCore’s business, operating results and performance financial nce of electroCore, and all actions that electroCore has and may take in response to COVID-19 and any expectations that electroCore may have in this regard, the competition in the industry in which electroCore operates and terms and conditions of the Marlet. All forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. , unless Required by law. Investors should review all information set forth in this document and should also refer to the risk factor disclosure set forth in reports and other documents filed by electroCore with the SEC available at www.sec.gov.


About Author

Comments are closed.